Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market, By Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System, and Others), Application (Biologics and Medical Research), End-user (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales and Others) - Industry Trends and Forecast to 2030.
Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Analysis and Insights
The Asia-Pacific Chinese Hamster Ovary (CHO) market is a vital component of the biopharmaceutical industry, driven by the escalating demand for biologics and therapeutic proteins. CHO cells are a preferred choice for biopharmaceutical production due to their ability to efficiently express complex proteins with proper post-translational modifications.
One of the major drivers for the Asia-Pacific Chinese Hamster Ovary (CHO) market is the growing demand for biopharmaceuticals. CHO cells are widely used in the production of biopharmaceuticals, including monoclonal antibodies, vaccines, and other therapeutic proteins. With an aging population and increasing healthcare needs, there is a rising demand for these advanced medicines across Asia-Pacific. CHO cells offer a reliable and efficient platform for the large-scale production of biopharmaceuticals, making them a critical component of the biomanufacturing process. As a result, the Asia-Pacific CHO cell market is experiencing steady growth as pharmaceutical companies and biotechnology firms seek to meet the demand for innovative therapies and vaccines, further fueling the adoption of CHO cell-based production systems. This trend is expected to continue, making the Asia-Pacific CHO cell market a significant player in the global biopharmaceutical industry.
However, One of the challenges faced by the Asia-Pacific Chinese Hamster Ovary Cells (CHO) market is regulatory complexity and compliance, which can impact the development and production of biopharmaceuticals.
The Asia-Pacific Chinese Hamster Ovary (CHO) cells market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 9.9% in the forecast period of 2023 to 2030 and is expected to reach USD 159,123.92 Thousand by 2030 from USD 77,040.79 thousand in 2022.
Asia-Pacific Chinese Hamster Ovary (CHO) cells market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for the safe distribution of machine and drug products are the major drivers that propelled the demand of the market in the forecast period.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Type (Services and Product), System (Metabolic Selection System, Antibiotic Selection System, and Others), Application (Biologics and Medical Research), End-user (Biopharmaceutical Companies, Biotechnology Companies, Clinical Development and Manufacturing Organizations, Clinical Research Organizations, Academic Institutes and Research Organizations, and Others), Distribution Channel (Direct Tenders, Retail Sales and Others)
|
|
Countries Covered
|
China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, Curia Global, Inc. among others.
|
Market Definition
Chinese Hamster Ovary (CHO) cells are a type of mammalian cell line commonly used in biotechnology and biomedical research, particularly in the field of cell culture and bioprocessing. These cells have become essential tools in biotechnology and biomedical research. CHO cells are known for their adherence to culture surfaces, robust growth characteristics, and ability to express recombinant proteins. Their popularity stems from their similarity to human cells, making them suitable for studying biological processes and producing biopharmaceuticals.
Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Dynamics
Drivers
- Rising use of CHO cells in the genetic study
The rising use of CHO cells in genetic studies is a significant driver for the Asia-Pacific Chinese Hamster Ovary (CHO) market. CHO cells have gained prominence in genetic research due to their adaptability and versatility in genetic manipulation and expression systems. Researchers and biotechnologists across Asia-Pacific are increasingly relying on CHO cells to investigate various aspects of genetics, including gene expression, genome editing, and functional genomics.
CHO cells provide a stable and well-characterized platform for genetic studies, making them an essential resource for understanding gene function, protein expression, and the development of new therapeutic agents. This heightened interest in genetic research using CHO cells not only fuels the demand for CHO cells but also drives innovations in biotechnology and genetic engineering techniques. Consequently, the Asia-Pacific CHO cell market is experiencing growth as it caters to the expanding needs of the scientific community engaged in genetic research and biotechnology, further solidifying its position in the life sciences sector.
- Growing demand for biopharmaceuticals
The growing demand for biopharmaceuticals is a key driver for the Asia-Pacific Chinese Hamster Ovary (CHO) market. CHO cells play a vital role in the production of biopharmaceuticals, such as monoclonal antibodies, vaccines, and therapeutic proteins. With an aging population and increasing healthcare needs in Asia-Pacific, there is a rising demand for these advanced medicines. CHO cells offer a reliable and efficient platform for large-scale biopharmaceutical production, making them indispensable for the biomanufacturing process. As pharmaceutical companies and biotechnology firms seek to meet the demand for innovative therapies and vaccines, the Asia-Pacific CHO cell market is experiencing steady growth, reinforcing its crucial role in the biopharmaceutical industry.
Opportunity
-
Continuous development of cell culture technologies
The continuous development of cell culture technologies is a critical aspect of biopharmaceutical manufacturing and biotechnology research. These advancements play a pivotal role in improving the production of biological drugs, vaccines, and other biotechnological products. The benefits of ongoing developments in cell culture technologies are
Enhanced Cell Line Development: One of the primary areas of focus in cell culture technology is the development of high-productivity cell lines. Scientists are continually refining methods for selecting, engineering, and optimizing mammalian cell lines, including CHO cells. This involves genetic modifications to increase cell growth rates, protein expression levels, and product quality attributes. These advancements result in more efficient and cost-effective biopharmaceutical production.
Improved Culture Media: Cell culture media are essential for providing cells with the necessary nutrients, growth factors, and environmental conditions for optimal growth and protein expression. Ongoing research aims to develop advanced culture media formulations that enhance cell viability, productivity, and product quality while minimizing production costs. This includes the optimization of chemically defined media to reduce reliance on animal-derived components, improving medium recycling strategies, and tailoring media for specific cell lines and biological products.
Restraints/Challenges
- Time-consuming and inconsistency in the CHO cell line development process
The Asia-Pacific Chinese Hamster Ovary (CHO) market faces the challenge of a time-consuming and often inconsistent CHO cell line development process. Developing stable and high-yielding CHO cell lines for biopharmaceutical production can be a lengthy and resource-intensive endeavor. Variability in cell line performance and characteristics can lead to unpredictability in production, which affects the overall efficiency and cost-effectiveness of biopharmaceutical manufacturing.
The need to optimize and characterize cell lines, select appropriate clones, and achieve consistent productivity levels can extend development timelines and increase operational costs. This challenge not only affects time-to-market for new biopharmaceuticals but also adds complexity to regulatory compliance and quality assurance efforts. Consequently, addressing the time-consuming and inconsistent nature of the CHO cell line development process is essential to enhance the competitiveness of the Asia-Pacific CHO cell market in the biopharmaceutical industry.
- High cost of CHO cell-based production
The high cost of CHO cell-based production is a significant restraint in the biopharmaceutical manufacturing industry. Several factors contribute to the elevated costs are mentioned below.
The upstream process in CHO cell-based production is complex. It involves the cultivation of mammalian cells in bioreactors, which necessitates strict control over various parameters such as temperature, pH, oxygen levels, and nutrient supply. Maintaining these optimal conditions for cell growth and protein expression requires specialized equipment and skilled personnel, adding to the overall cost.
Cell line development is another resource-intensive step. Creating highly productive CHO cell lines involves selecting suitable cells and genetically modifying them to express the desired therapeutic protein efficiently. This process involves substantial research efforts, extensive genetic engineering, and rigorous screening, all of which demand time and resources.
In addition, the cost of culture media and nutrients for CHO cells is a significant contributor. These cells require specific growth media containing essential nutrients, growth factors, and supplements. The expense of procuring these high-quality culture media can accumulate significantly over large-scale production runs. Researchers continually work on optimizing media formulations to reduce costs while maintaining cell performance.
Recent Developments
- In July 2023, Lonza has introduced the TheraPRO CHO Media System, an innovative cell culture solution designed to streamline procedures and enhance both productivity and protein quality, particularly in conjunction with GS-CHO cell lines. This product launch is aimed at assisting pharmaceutical and biotechnology enterprises in their efforts to produce therapeutic proteins of higher quality and expedite their time-to-market
- In October 2022, after the favorable reception of the Gibco Freedom CHO-S Cell Line Development Kit, ProBioGen and Thermo Fisher Scientific collaborated once more to create an enhanced solution: the Gibco Freedom ExpiCHO-S Cell Line Development Kit. This advanced platform enables users to establish cell lines suitable for clinical development, even without possessing their own initial cells, vectors, or prior expertise in the domain. Leveraging their profound knowledge in cell line and process development, ProBioGen has significantly enhanced the performance of the Freedom ExpiCHO-S Kit
Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Scope
Asia-Pacific Chinese Hamster Ovary (CHO) cells market is categorized into five notable segments based on type, system, application, end-user, and distribution channel.The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Services
- Products
On the basis of type, the Asia-Pacific Chinese Hamster Ovary (CHO) market is segmented into services and product.
System
- Metabolic Selection System
- Antibiotic Selection System
- Others
On the basis of systems, the Asia-Pacific Chinese Hamster Ovary (CHO) market is segmented into metabolic selection system, antibiotic selection system, and others.
Application
- Biologics
- Medical Research
On the basis of application, the Asia-Pacific Chinese Hamster Ovary (CHO) market is segmented into biologics and medical research.
End-User
- Biopharmaceutical Companies
- Biotechnology Companies
- Clinical Development and Manufacturing Organizations
- Clinical Research Organizations
- Academic Institutes and Research Organizations
- Others
On the basis of end-user, the Asia-Pacific Chinese Hamster Ovary (CHO) market is segmented into biopharmaceutical companies, biotechnology companies, clinical development and manufacturing organizations, clinical research organizations, academic institutes and research organizations, and others.
Distribution Channel
- Direct Tenders
- Retail Sales
- Others
On the basis of distribution channel, the Asia-Pacific Chinese Hamster Ovary (CHO) market is segmented into direct tenders, retail sales, and others.
Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Regional Analysis/Insights
The Asia-Pacific Chinese Hamster Ovary (CHO) cells market is categorized into five notable segments based on type, system, application, end-user, and distribution channel.
The countries covered in this market report are China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific
China dominates Asia-Pacific region and expected to grow with the highest CAGR in the forcast period due to country's strong research and development capabilities in biopharmaceutical industries.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Asia-Pacific Chinese Hamster Ovary (CHO) Cells Market Share Analysis
Asia-Pacific Chinese Hamster Ovary (CHO) cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the Asia-Pacific Chinese Hamster Ovary (CHO) cells market.
Some of the major players operating in the Asia-Pacific Chinese Hamster Ovary (CHO) cells market are Thermo Fisher Scientific Inc., AcceGen, RayBiotech Life, Inc., CLS Cell Lines Service GmbH, BPS Bioscience, Inc., GenTarget Inc., Merck KGaA, Abeomics, Applied Biological Materials Inc. (abm), ATCC, Sartorius AG, Lonza, Horizon Discovery Ltd., Cytiva, Curia Global, Inc. among others. among others.
SKU-